loader

LYSA presentations in June 2021 international congresses

 

 

 

 

Oral communication by Charles Herbaux

 

Oral communication by Steven Le Gouill

 

Poster by Yassine Al Tabaa

 

  • Early Positron Emission Tomography Response-Adapted Treatment in Localized Diffuse Large B-Cell Lymphoma (aaIPI=0): Results of the Phase 3 LYSA LNH-09-1B Trial

Oral communication 005 in plenary session by Serge Bologna

 

  • Defining ultra-high-risk DLBCL patients prior to initial treatment based on an integrative host and disease prognostic score (from REMARC study)

Oral communication 017 in general session 2: Catherine Thieblemont

 

  • Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL): clinico-pathological analysis of a multicenter European cohort.

Oral communication 044 in session 6: Doriane Cavalieri

 

  • Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients: a LYSA study.

Oral communication 050 in session 7: Vincent Camus

 

  • First results of DLBCL patients treated with CAR-T cells and enrolled in DESCAR-T registry, a French real-life database for CAR-T cells in hematologic malignancies.

Oral communication 084 in session 13: Steven Le Gouill

 

  • Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Marginal Zone Lymphoma: primary analysis of a phase 2 trial from LYSA

E-poster & Abstract Book Nr. 145: Charles Herbaux

 

  • Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Follicular Lymphoma: primary analysis of a phase 2 trial from LYSA

E-poster & Abstract Book Nr. 110: Guillaume Cartron

 

  • Circulating tumor DNA load and total metabolic tumor volume in Diffuse Large B Cell Lymphoma (DLBCL) patients treated by R-CHOP – From REMARC, a LYSA study

E-poster by Catherine Thieblemont

 

  • High adipose tissue density is a negative prognostic factor in DLBCL patients treated by R-CHOP, independent from TMTV and PS-From the REMARC study

E-poster by Catherine Thieblemont

 

  • Selinexor in Combination with R-GDP for Patients with Relapsed/ Refractory B-Cell Lymphoma: Preliminary results of the SELINDA phase Ib LYSA study (EUDRACT Number: 2015-005612-15)

E-poster by Marie Maerevoet

 

  • Long-term outcomes of elderly patients treated with frontiline R-CHOP: update of the LNH03-6B trial

E-poster by Vincent Camus

 

  • Impact of DUSP22 rearrangement on the prognosis of systemic ALK-negative anaplastic large cell lymphoma : a LYSA and TENOMIC study

E-poster by David Sibon

 

  • 199 – Brentuximab vedotin as consolidation treatment in patients with stage I/II classical Hodgkin’s lymphoma and a positive FDG-PET after 2 cycles of ABVD : a LYSA phase 2 study

E-poster by Thomas Gastinne

 

  • Prospective evaluation of lymphoma response to immunomodulatory therapy criteria (lyric) in GATA trial from the LYSA group

E-poster & Abstract Book n°245 by Yassine Al Tabaa

 

  • Gender disparities in quality of life of French patients one year after the diagnosis of Lymphoma, a LYSA study

E-poster & Abstract Book n°280 by Caroline Besson

 

  • A widespread T-cell exhaustion pattern is frequent in the tumor microenvironment of relapsed/refractory B-cell Lymphoma patients and could be circumvented by PDL1 blockade.

Abstract book by Camille Laurent

Next

eget dolor. nec et, porta. Aenean